CVS HEALTH: CVS Pharmacy Statement Regarding Zantac and Other Ranitidine Products


CVS Health issued the following announcement on Sept. 28.

CVS Pharmacy has suspended the sale of all Zantac brand and CVS Health brand ranitidine products until further notice. This action is being taken out of an abundance of caution due to a recent Product Alert from the U.S. Food and Drug Administration (FDA) that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen.

The FDA is continuing to evaluate whether low levels of NDMA in ranitidine pose a risk to patients. The levels that FDA is finding in ranitidine from preliminary tests barely exceed amounts found in common foods.

The FDA is not recommending that patients stop taking ranitidine at this time. However, customers who purchased these products can return them to CVS for a refund.

Ranitidine is an H2 Blocker that is taken to provide heartburn relief. CVS Pharmacy will continue to sell other over-the-counter H2 Blockers, including Pepcid, Tagamet and its respective generic equivalents, famotidine and cimetidine.

Consumers seeking alternate therapy to treat their condition should speak with their healthcare provider or a CVS pharmacist. CVS pharmacists are always available to discuss any questions or concerns that customers may have about their medications.

Original source can be found here.

Want to get notified whenever we write about CVS Health ?

Sign-up Next time we write about CVS Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

CVS Health

More News

Metro Business Network